CardioNet Takes a Beating, But Keeps on Ticking [View article]
BIEL has experienced a huge run-up in share price on the pending 510(k) applications and new submissions expected to occur. Also, the FDA Panel recommendations to have stricter guidelines for Tylenol and combination pain drugs with acetaminophen will ultimately benefit BIEL. Not surprised to see the stock take a breather with next catalysts coming in the form of new 510(k) filings, marketing clearance for the pending submissions, and final FDA action on Tylenol
On Jul 28 10:52 PM DuckThis wrote:
> Mike: > I follow your posts enjoy your insights anf due dillgence. Off the > subject of this article how about your thoughts on biel. you spoke > to this one breifly in June. I was on the conference call today and > it all sounded goo, maybe too good. As I attempted to ask a question > I was disconnected. I want a time frame on audited finanical statements. > Not on my question for them but your thoughts would be useful.
CardioNet Takes a Beating, But Keeps on Ticking [View article]
On Jul 28 10:52 PM DuckThis wrote:
> Mike:
> I follow your posts enjoy your insights anf due dillgence. Off the
> subject of this article how about your thoughts on biel. you spoke
> to this one breifly in June. I was on the conference call today and
> it all sounded goo, maybe too good. As I attempted to ask a question
> I was disconnected. I want a time frame on audited finanical statements.
> Not on my question for them but your thoughts would be useful.
Health IT Poised to Rebound Post-Election [View article]
www.investinwhoyouare....
Health IT Poised to Rebound Post-Election [View article]